This HTML5 document contains 175 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
n12http://dx.doi.org/10.1093/ANNONC/
schemahttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n9http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q34636081
rdf:type
wikibase:Item
schema:description
scienca artikolo 2012 nî lūn-bûn wetenschappelijk artikel vědecký článek 2012年论文 مقالهٔ علمی vitenskapelig artikkel 2012年論文 artigo científico 2012年論文 2012年论文 2012年论文 мақолаи илмӣ научни чланак vitskapeleg artikkel artikull shkencor 2012年論文 article científic artigo científico (publicado na 2012) επιστημονικό άρθρο научна статия 2012년 논문 scientific article სამეცნიერო სტატია articolo scientifico מאמר מדעי article scientific 2012年论文 artículu científicu espublizáu en 2012 мақолаи илмӣ naučni članak tudományos cikk научни чланак ২০১২-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ artículo científico publicado en 2012 bilimsel makale 2012 թուականի Փետրուարին հրատարակուած գիտական յօդուած مقالة علمية article scientifique (publié 2012) 2012年の論文 tieteellinen artikkeli artykuł naukowy videnskabelig artikel (udgivet 2012) 2012年论文 наукова стаття, опублікована в лютому 2012 teaduslik artikkel vetenskaplig artikel bài báo khoa học 2012年論文 سائنسی مضمون articol științific 2012 թվականի փետրվարին հրատարակված գիտական հոդված 2012年论文 artigo científico (publicado na 2012) mokslinis straipsnis artikulong pang-agham 2012年論文 научная статья vedecký článok บทความทางวิทยาศาสตร์ wissenschaftlicher Artikel
p:P577
wds:Q34636081-DB500362-AF57-4F22-A6F7-EB4129CFE3FE
wdt:P577
2012-02-21T00:00:00Z
p:P2860
wds:Q34636081-58656419-5CBD-4703-BD92-7B033F22F035 wds:Q34636081-7A5EAE3D-F347-4859-B466-6377B5DC47C1 wds:Q34636081-8788F035-A32F-4810-A876-6480AC725242 wds:Q34636081-92F00EEF-7936-4888-981F-8967C544B8D8 wds:Q34636081-9A6BEA49-C5CC-438D-897F-46B87B17DD8F wds:Q34636081-A269B5D6-AB63-464A-97E1-FE4AB8EF6C48 wds:Q34636081-A4C535E6-E1F7-4482-8C95-A09BA4463FD4 wds:Q34636081-AEAB7A69-4D3D-4EF6-9EE7-CCBCF740DA44 wds:Q34636081-B435AD81-E9A9-43F0-92B6-3CC561A46D2E wds:Q34636081-BFB62C2C-8989-4C8F-A1F0-2FA35F74C342 wds:Q34636081-C6480687-6046-4AA0-9032-02ACA8AE8425 wds:Q34636081-DDFD9666-C1C8-4992-85CB-C1DF6B71818C wds:Q34636081-E8F03EB2-C205-4ED2-B02C-268A0906BD91 wds:Q34636081-F067A420-CBBA-4FF9-A061-0032FC693AB9 wds:Q34636081-F2C6508A-40A2-43FC-B322-7AEA5EC4C039 wds:Q34636081-F328F73E-97C3-459E-A151-AB45751A7729 wds:Q34636081-FE658BDA-D7CE-425F-96BE-37184CD65E4F wds:Q34636081-07112420-A04F-45F6-9677-9E2202E1B9D5 wds:Q34636081-111B11C6-D87C-4D96-B66C-D78D1D19C39E wds:Q34636081-11A7A52B-11CD-45C2-A158-8798D12AF8D7 wds:Q34636081-12152271-1D5A-49C5-A940-2E0564690E09 wds:Q34636081-196CB39C-E521-4755-BE3B-87D4FFDB7F68 wds:Q34636081-1E97A904-5DC7-46A9-A7D5-8091B7E90DB8 wds:Q34636081-287D03F0-67E6-4D29-9741-0A80736FD8A6 wds:Q34636081-288F31F2-AB5F-4FCC-8ACC-D79863546C7E wds:Q34636081-34AFA2A5-1903-48DE-9CDB-FF2001844A3A wds:Q34636081-42D1BF9A-CD6E-4D2F-B66C-11A6D3F5BFD9 wds:Q34636081-46E85CAB-AC6C-4B26-8F61-DFC18D8E6D35
wdt:P2860
wd:Q33561602 wd:Q28246204 wd:Q33817421 wd:Q59236733 wd:Q44837747 wd:Q40634392 wd:Q34560089 wd:Q34551403 wd:Q46610792 wd:Q27860904 wd:Q34587751 wd:Q43239053 wd:Q34652070 wd:Q34506729 wd:Q46560498 wd:Q29618610 wd:Q40305502 wd:Q40217664 wd:Q28268831 wd:Q53718715 wd:Q40667580 wd:Q39707661 wd:Q33710999 wd:Q36157329 wd:Q36426453 wd:Q35212601 wd:Q34341750 wd:Q34743609
p:P2093
wds:Q34636081-DD025612-241E-4195-8BE4-A0263E133FEA wds:Q34636081-8A209782-89A9-4D1A-8E92-EE0634DF6D8F wds:Q34636081-5616D1D9-A8FE-4A1F-B530-3FD0A1A83710 wds:Q34636081-1EC6838D-A0BF-49DA-B11E-C15557448C77 wds:Q34636081-3C5A47FF-EA0A-4357-A06D-24602BCF97DE wds:Q34636081-3839950D-964F-431A-9D34-6208961EF0C6 wds:Q34636081-3B038135-CF16-4519-A3F2-EFC339C819D3 wds:Q34636081-0D36EE58-C754-48B3-9A60-1F8478B5A956
wdt:P2093
G D Demetri M Schlemmer S Yazji I Galetic P Reichardt H Gelderblom B Bui-Nguyen Y Hsu
rdfs:label
Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib. Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib. Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib.
skos:prefLabel
Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib. Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib. Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib.
schema:name
Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib. Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib. Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib.
p:P50
wds:Q34636081-BD7A406C-A474-4582-A256-B4911E388014 wds:Q34636081-A83ECBEA-3532-4886-95D6-38CE4614508F wds:Q34636081-489761D4-9546-41B0-AF86-E6581291DF6E
wdt:P50
wd:Q37842284 wd:Q45893828 wd:Q6076539
p:P1476
wds:Q34636081-D9221FB2-AFB1-4399-967F-6619AE6B039E
wdt:P1476
Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib
p:P304
wds:Q34636081-8D8B76BD-7857-4941-8834-DC6C372F57FE
wdt:P304
1680-1687
p:P31
wds:Q34636081-0810658A-42DA-4117-BF0F-48F41EB3BDA3
wdt:P31
wd:Q13442814
p:P921
wds:Q34636081-3E742640-3DE8-43BD-94E9-A7FA2DD8FA31 wds:Q34636081-D7C87C91-4F13-4E40-82DB-59805880095F
wdt:P921
wd:Q177094 wd:Q181600
p:P698
wds:Q34636081-006DC54D-D877-4445-BAEE-436A3F8D3875
wdtn:P698
n9:22357255
wdt:P698
22357255
p:P1433
wds:Q34636081-9C3FEEAC-5491-4F9C-8927-CC8C4F21089D
wdt:P1433
wd:Q326122
p:P433
wds:Q34636081-4CD8965F-6BA1-4CCB-8DAC-B0AC8FB1E495
p:P478
wds:Q34636081-9E562212-4924-4C46-8F82-0B9B53839351
wdt:P433
7
wdt:P478
23
p:P356
wds:Q34636081-C532AF54-69B6-408C-A231-DECE30803191
wdtn:P356
n12:MDR598
wdt:P356
10.1093/ANNONC/MDR598
p:P5875
wds:Q34636081-1482E8C6-9F2B-4263-84F1-5D2B82A24CE8
wdt:P5875
221853904